Figure 5.

Schematics showing allosteric regulation using synthetic binding proteins. (A) Monobody binding to the SH2 domain of ABL kinase disrupts the intramolecular, domain‐domain interaction, which leads to kinase inhibition.45, 70 (B) Monobody binding to a dimerization interface of RAS disrupts the RAS‐RAF hetero‐trimer and inhibits RAS‐mediated activation of RAF.59 (C) Tandem DARPin disrupts the dimer formation of HER2, thereby inhibiting the kinase activity of HER2. Figure based on Jost et al.71.